Kenneth Pugh BTG

Consistent Leadership for BTG and Other Companies

With over 25 years' experience in the industry, Kenneth Pugh served as a vice president with international responsibilities for the global healthcare company BTG plc from its PA office. Kenneth Pugh’s areas of expertise range from commercialization, general management, strategic planning and profit enhancement to worldwide expansion and new product research & development. 

Ken Pugh’s service to BTG began in 2011, when he oversaw commercialization and franchise achievements for Voraxaze, a medication for cancer therapy-related, severe kidney conditions. As he assumed greater responsibilities, he supervised the creation of commercialization plans, operational efficiencies, educational resources, strategies, pricing, and media items for new cancer treatments, as well as vascular interventions. 

Prior to that, Ken Pugh spent a decade at Janssen Biotech (formerly known as Centocor), a leader in immunological and cancer-related therapies. He took charge of collaborating with universities and hospitals, leading a $1.5 billion program that dealt with arthritis and rheumatism. Previously, he served as a national account executive for Kantar Health and in roles of increasing responsibilities in sales & marketing at Merck & Co. Inc. He has won eight awards for sales/marketing excellence at Merck and Janssen. At BTG, Ken Pugh won the 2016 Society of Interventional Radiology Industry Leader Award. 

Ken Pugh is now an independent consultant for Guidepoint, Gerson Lehrman Group, and Coleman Research and holds a board seat at Prohibix, an early stage medical technology company focusing on minimally invasive therapies for cancer, heart disease and osteoarthritis. He holds an MBA from Drexel University.

Phoenixville, Pennsylvania, US